English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

See related article, pp 846–855 Natriuretic peptides (NPs) include atrial NP (ANP), B-type NP, and C-type NP. NPs exert cardiovascular protective effects through interaction with their receptors. There are 2 major classes of NP receptors (NPRs): guanylyl cyclase–coupled receptors A and B (NPR-A and NPR-B) and inhibitory guanine nucleotide regulatory protein (inhibitory G protein)–coupled receptor C (NPR-C; Figure). The cardiovascular protective effects of NPs have been primarily attributed to the elevation of intracellular cGMP via NPR-A and NPR-B.1 NPR-C, initially identified as a clearance receptor,2 has been shown to inhibit adenylyl cyclase via the α subunit of the inhibitory G protein and to stimulate phospholipase C signaling via the βγ subunits of the same inhibitory G protein.3 NPR-C is widely distributed in many tissues and cell types and has higher density than …

Is Natriuretic Peptide Receptor C a New Target for Hypertension Therapeutics?